Michael O'Grady - Apr 25, 2025 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
Director
Signature
/s/ Michael G. O'Grady by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Apr 25, 2025
Transactions value $
$0
Form type
4
Date filed
4/29/2025, 06:06 PM
Previous filing
Mar 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +1.64K +44.41% $0.00 5.32K Apr 25, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +3.77K $0.00 3.77K Apr 25, 2025 Common Shares 3.77K $128.40 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2 Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.